“…Although older implant types are associated with a high risk of failure and subsequent revision rates of up to 25% (Holme et al., 2021; Kirkeby et al., 2021; Remy et al., 2020), the revision rates of dual-mobility implants, such as the Touch® (KeriMedical, Switzerland) or Moovis® (Stryker, USA) devices, have been reported to be below 5% in the first 3 years after arthroplasty (Dremstrup et al., 2021; Falkner et al., 2023; Froschauer et al., 2021; Gonzalez-Espino et al., 2021; Lussiez et al., 2021; Tchurukdichian et al., 2019). Further complications include de Quervain stenosing vaginosis and trigger thumb (Froschauer et al., 2021; Gonzalez-Espino et al., 2021; Lussiez et al., 2021), but an analysis of the adverse events related to these implant types and their treatment is currently lacking.…”